Takara Bio has been granted a patent for methods of depleting target nucleic acids from a collection. The process involves using nucleic acid guided nucleases to selectively separate target nucleic acids from non-target ones. Compositions and kits for practicing these methods are also provided. GlobalData’s report on Takara Bio gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Takara Bio Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Takara Bio, was a key innovation area identified from patents. Takara Bio's grant share as of February 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

Selective separation of target nucleic acids from a composition

Source: United States Patent and Trademark Office (USPTO). Credit: Takara Bio Inc

A recently granted patent (Publication Number: US11884963B2) discloses a method for selectively separating target nucleic acids from a composition. The method involves contacting the composition with cleavage-deficient nucleases and guide nucleic acids to form a complex where the guide nucleic acids specifically hybridize with the target nucleic acids. This complex is then separated from the composition, effectively isolating the target nucleic acids from non-target nucleic acids. The patent claims cover various aspects of the method, including the types of target nucleic acids, the nature of guide nucleic acids (RNA or DNA), and the selection of cleavage-deficient nucleases such as Cas nucleases or Argonaute nucleases.

Furthermore, the patent also describes a method for producing a composition selectively enriched with target nucleic acids. This method involves contacting the composition with cleavage-deficient nucleases and guide nucleic acids to form a complex, which is then separated to produce a composition enriched with the target nucleic acids. The patent claims specify the types of target nucleic acids, guide nucleic acids, and cleavage-deficient nucleases that can be used in this enrichment process. Additionally, the patent covers the use of tags on the cleavage-deficient nucleases for immobilizing the complex on a solid phase during separation, providing a practical application of the method in laboratory settings.

To know more about GlobalData’s detailed insights on Takara Bio, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.